Pictet Asset Management
CERE

Pictet Asset Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Pictet Asset Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-9,563
Closed -$391K – 2063
2024
Q2 		$391K Hold
9,563
– – ﹤0.01% 1387
2024
Q1 		$404K Hold
9,563
– – ﹤0.01% 1398
2023
Q4 		$405K Buy
+9,563
New +$275K ﹤0.01% 1370

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Pictet Asset Management's CERE Position: Q3 2024 in Review

Pictet Asset Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 9,563 shares — an estimated $391K sold.

Pictet Asset Management first reported a position in CERE in Q4 2023 and held it in 3 quarters. The position peaked at $405K in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Pictet Asset Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Pictet Asset Management sold 9,563 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $391K.
  • Pictet Asset Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 3 quarters.
  • Pictet Asset Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $405K in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Pictet Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.